MannKind Corporation (NASDAQ:MNKD - Free Report) - Investment analysts at HC Wainwright issued their FY2025 EPS estimates for MannKind in a research note issued to investors on Wednesday, July 16th. HC Wainwright analyst expects that the biopharmaceutical company will post earnings per share of $0.19 for the year. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind's FY2026 earnings at $0.26 EPS, FY2027 earnings at $0.36 EPS, FY2028 earnings at $0.57 EPS and FY2029 earnings at $0.77 EPS.
MannKind (NASDAQ:MNKD - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. MannKind had a net margin of 10.12% and a negative return on equity of 32.41%. The firm had revenue of $78.35 million for the quarter, compared to analyst estimates of $75.86 million. During the same period in the prior year, the firm earned $0.05 earnings per share. The business's quarterly revenue was up 18.1% compared to the same quarter last year.
Other equities analysts have also issued reports about the stock. Wall Street Zen upgraded shares of MannKind from a "hold" rating to a "buy" rating in a research note on Friday. Mizuho started coverage on MannKind in a report on Thursday, April 10th. They issued an "outperform" rating and a $12.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $10.14.
Check Out Our Latest Report on MNKD
MannKind Price Performance
MannKind stock opened at $3.76 on Monday. The stock's fifty day moving average is $4.02 and its two-hundred day moving average is $4.86. The stock has a market cap of $1.14 billion, a PE ratio of 37.60 and a beta of 0.96. MannKind has a 1-year low of $3.51 and a 1-year high of $7.63.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Farther Finance Advisors LLC raised its position in shares of MannKind by 1,379.2% in the second quarter. Farther Finance Advisors LLC now owns 7,396 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 6,896 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of MannKind during the fourth quarter worth about $37,000. Blueshift Asset Management LLC purchased a new stake in shares of MannKind in the first quarter worth about $51,000. Kapitalo Investimentos Ltda acquired a new stake in MannKind in the second quarter valued at approximately $51,000. Finally, Sowell Financial Services LLC purchased a new stake in MannKind during the 1st quarter worth $56,000. 49.55% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, Director Steven B. Binder sold 80,144 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $4.69, for a total value of $375,875.36. Following the sale, the director directly owned 1,006,611 shares in the company, valued at $4,721,005.59. The trade was a 7.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David Thomson sold 32,179 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $4.68, for a total transaction of $150,597.72. Following the transaction, the executive vice president owned 772,427 shares of the company's stock, valued at $3,614,958.36. This trade represents a 4.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 266,198 shares of company stock worth $1,143,244. Corporate insiders own 3.00% of the company's stock.
About MannKind
(
Get Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
